Clinical outcomes of the placement of a drug-eluting stent with the use of Rotablator™ in dialytic patients: in comparison with non-dialytic patients.
Much remains unknown about the clinical outcomes of drug-eluting stent (DES) implantations following ablation by the Rotablator™ in dialytic patients. The purpose of this study was to examine these outcomes. Of the 43 patients who underwent elective DES implantation following ablation with the Rotablator™-17 lesions on 12 dialytic patients were designated to Group H and 54 lesions on 31 non-dialytic patients were designated to Group N. QCA data, the rate of restenosis and the avoidance rate of cardiac events at the chronic phase (920 ± 446 days) were studied. The age of patients in Group N was significantly older (60 ± 8 years old in Group H vs. 73 ± 7 in Group N, p < 0.05). The rate of DM complication was significantly higher in Group H (75.0% in Group H vs. 32.0% in Group N, p < 0.05). The late loss was 1.18 ± 0.97 mm in Group H and 0.38 ± 0.53 mm in Group N, or significantly greater in Group H (p < 0.05). The restenosis rate was also higher in group H. (42.9% in Group H and 6.0% in Group N). The avoidance rate of cardiac events at the chronic phase was significantly lower in Group H. The study suggested that in patients who received DES with the use of the Rotablator™, clinical outcomes were poorer in dialytic patients than in non-dialytic patients.